ZIVO Bioscience, Inc.
ZIVO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.37 | 0.01 | 0.11 | 0.07 |
| FCF Yield | -5.88% | -285.99% | -30.21% | -31.13% |
| EV / EBITDA | -5.39 | -0.29 | -2.54 | -1.46 |
| Quality | ||||
| ROIC | 5,128.62% | 390.59% | -2,009.40% | -147.41% |
| Gross Margin | 31.14% | 41.99% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.32 | 0.75 | 0.81 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 25.63% | 18.34% | -4.40% | -162.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | -0.01 | 0.16 | 0.96 |
| Interest Coverage | -582.50 | -14.13 | -655.60 | -38.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,495.85 | -26,478.28 | 0.00 | 0.00 |